Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | The importance of improving diagnosis in MPNs and tailoring treatment approaches

Jerry Spivak • 26 Aug 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Interferon

Jerry Spivak, MD, Johns Hopkins University School of Medicine, Baltimore, MD, shares his thoughts on the importance of improving diagnosis in myeloproliferative neoplasms (MPNs) and further comments on how treatment approaches should be tailored to different subgroups of patients. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Jerry Spivak

Polycythemia vera: myths, mechanisms, and management
Jerry Spivak • 24 Nov 2022
Polycythemia vera: disease outcomes, unmet needs and therapeutic strategies
Jerry Spivak • 10 Nov 2022
Challenges in the treatment and management of ET and the need to improve therapeutic approaches 5:21
Challenges in the treatment and management of ET and the need to improve therapeutic approaches
Jerry Spivak • 26 Aug 2022
The need to improve diagnostic criteria in PV and other challenges in the field 6:04
The need to improve diagnostic criteria in PV and other challenges in the field
Jerry Spivak • 26 Aug 2022

Related Videos

Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera 2:04
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
Aniket Bankar • 8 Dec 2025
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET 2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 8 Dec 2025
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms 1:39
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms
Roman Doll • 7 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals